Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 2,409 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Invasive Procedure Clear all

Conditions: Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions: Atezolizumab, Biopsy of Bladder, Cisplatin, Computed Tomography, Cystoscopy, Fluorouracil, Gemcitabine, Magnetic Resonance Imaging, Mitomycin, Quality-of-Life Assessment, Radiation Therapy, Survey Administration, Transurethral Resection of Bladder Tumor; Drug · Procedure · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 365
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 273 more

Conditions: Cancer
Interventions: Minimally-Invasive Procedure; Procedure
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Bladder Cancer, Metastatic Bladder Cancer, Invasive Bladder Cancer
Interventions: Avelumab; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Houston, Texas

Conditions: Risk Reduction
Interventions: Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation, Trivalent Salmonella Conjugate Vaccine (TSCV) Half-Strength Formulation, Trivalent Salmonella Conjugate Vaccine (TSCV) Dilutional Half-Strength Formulation, Placebo; Biological · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 49 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Bacteremia, Fungemia
Interventions: Not listed
Lead sponsor: Accelerate Diagnostics, Inc.; Industry
Eligibility: Not listed
Enrollment: 4,009 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 14
States / cities: Gilbert, Arizona • Tucson, Arizona • Los Angeles, California + 10 more

Conditions: Arteriosclerosis of Coronary Artery Bypass Graft
Interventions: Minimally invasive coronary artery bypass graft surgery; Procedure
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Staten Island, New York

Conditions: Bladder Cancer
Interventions: Nivolumab, Ipilimumab, Radical cystectomy; Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Ductal Breast Carcinoma In Situ, Early-Stage Breast Carcinoma, Invasive Breast Carcinoma, Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7
Interventions: Laboratory Biomarker Analysis, Partial Breast Irradiation, Questionnaire Administration; Other · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 50 Years and older · Female only
Enrollment: 928 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 15
States / cities: Jacksonville, Florida • Atlanta, Georgia • Indianapolis, Indiana + 11 more

Conditions: Liver Transplant Rejection, Liver Transplant Failure and Rejection
Interventions: N/A-Observational Study; Other
Lead sponsor: St. Louis University; Other
Eligibility: 1 Year and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hearing Loss, Conductive, Hearing Loss, Unilateral
Interventions: Adhear Bone Conduction System, Bone anchored hearing aid (BAHA); Device
Lead sponsor: University of Miami; Other
Eligibility: 2 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Lymphoma
Interventions: Cardiac Magnetic Resonance Scan; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Gastric Cancer, Invasive Breast Cancer, in Situ Breast Cancer, Mantle Cell Lymphoma, Larynx Cancer, Bladder Cancer
Interventions: Viewray MRIdian® Linac; Radiation
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Bladder Cancer, Recurrent Bladder Cancer, Non-muscle Invasive Bladder Cancer (NMIBC)
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Tampa, Florida • Iowa City, Iowa • Chapel Hill, North Carolina + 3 more

Conditions: Cerebral Palsy, Perinatal Stroke, Periventricular Leukomalacia
Interventions: Active tDCS, Sham tDCS; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 7 Years to 21 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Trauma
Interventions: Radical-7 Pulse CO-Oximeter and sensor; Device
Lead sponsor: Masimo Corporation; Industry
Eligibility: 16 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer Stage IV, Unresectable Locally Advanced Invasive Breast Cancer, Metastatic Invasive Breast Cancer
Interventions: Palbociclib, Bazedoxifene; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Aspergillos, Mucormye, Dimorphic, Other Molds, Non-Aspergillos, Non-Mucormycosis
Interventions: [18F]-Fluorocellobiose ([18F]FCB); Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-muscle Invasive Bladder Cancer (NMIBC)
Interventions: ABI-009, Gemcitabine; Drug
Lead sponsor: Aadi Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: New York, New York • Nashville, Tennessee

Conditions: Sepsis, Hypotension, Septic Shock
Interventions: NICOM; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Recurrent Cervical Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Uterine Corpus Sarcoma, Stage I Uterine Corpus Cancer, Stage I Uterine Sarcoma, Stage IA Cervical Cancer, Stage IB Cervical Cancer, Stage II Uterine Corpus Cancer, Stage II Uterine Sarcoma, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Uterine Corpus Cancer, Stage III Uterine Sarcoma, Stage IV Uterine Corpus Cancer, Stage IV Uterine Sarcoma, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer
Interventions: Medical Chart Review, Questionnaire Administration; Other
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Enrollment: 778 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 167
States / cities: Phoenix, Arizona • Tucson, Arizona • Burbank, California + 122 more

Conditions: High Risk for Invasive Breast Cancer
Interventions: Tamoxifen, Tamoxifen (Nolvadex); Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 30 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Uterine Leiomyoma, Fibroids
Interventions: Pirfenidone; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 35 Years to 50 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Aphasia, Non-fluent Aphasia, Stroke, Brain Injuries
Interventions: tDCS, Placebo; Device · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Duluth, Minnesota

Conditions: Reversal of Anticoagulant Treatment
Interventions: Octaplex (human prothrombin complex concentrate), Fresh frozen plasma; Biological
Lead sponsor: Octapharma; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

A Minimally-invasive Approach to Cytoreduction and HIPEC for Peritoneal Surface Malignancy

A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer

Salmonella Conjugates CVD 2000: Study of Responses to Vaccination With Trivalent Salmonella Conjugate Vaccine to Prevent Invasive Salmonella Disease

Clinical Performance of the Accelerate ID/AST System for Positive Blood Culture

Graft Patency Outcomes in Patients Undergoing Coronary Artery Bypass Grafting Via Minimally Invasive Coronary Surgery

A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy

Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer

Cytokeratin 18 Non-invasive Biomarker for Rejection in Liver Transplant Patients

Adhear Bone Conduction System

Cardiac Fibrosis by CMR in Patients With Cancer

CONFIRM: Magnetic Resonance Guided Radiation Therapy

Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2

Single-session tDCS in Cerebral Palsy

Evaluation of Non-Invasive Hemoglobin in Trauma Patients

A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer

Assessment of [18F]-Fluorocellobiose ([18F]FCB) Pharmacokinetics in Healthy Volunteers and Subjects With Invasive Mold Infections

Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer

Non-Invasive Cardiac Output Monitor (NICOM) for Goal-directed Fluid Resuscitation for Inpatients With Hypotension and/or Septic Shock

Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer

SHORTened Duration of TAMoxifen

Development of a Non-Invasive Treatment for Uterine Leiomyoma (Fibroids)

Combining tDCS and CILT in Non-fluent Aphasia

Study of Octaplex (Human Prothrombin Complex Concentrate) and Fresh Frozen Plasma in Patients Under Vitamin K Therapy Antagonist Needing Urgent Surgery or Invasive Procedures